Quantcast
Ebola Protein Blocks Bodys Counterattack On Virus

Ebola Protein Blocks Body's Counterattack On Virus

The Mount Sinai Hospital / Mount Sinai School of Medicine Findings provide framework for new drug development efforts One of the human body's first responses to a viral infection is to make and release signaling proteins called interferons,...

Latest Antivirals Stories

2014-08-18 16:27:33

DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Brivudine (CAS 69304-47-8) Market Research Report 2014" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Brivudine (CAS 69304-47-8) Market Research Report 2014 presents comprehensive data on brivudine markets globally and regionally (Europe, Asia, North America etc.) The report includes brivudine description, covers its application areas and related patterns. It...

2014-07-28 13:20:36

The Lancet Infected patients and could improve treatment uptake Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet. Both studies focused on hepatitis C genotype 1, which is the most common genotype in the USA, Europe, North Asia, Australia, and South America,...

2014-07-28 08:28:50

New study identifies potential alternatives to Gilead's Sovaldi PHILADELPHIA, July 28, 2014 /PRNewswire/ -- The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in...

2014-07-21 11:07:15

The JAMA Network Journals HIV-infected patients also infected with hepatitis C virus (HCV) who received a combination of the medications sofosbuvir plus ribavirin had high rates of sustained HCV virologic response 12 weeks after cessation of therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. The issue is being released early to coincide with the International AIDS Conference. Up to 7 million persons worldwide are infected with both human...

2014-07-15 12:28:37

Unprecedented Growth Will be Fuelled by Rapid Uptake of All-Oral, Interferon-Free Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that the hepatitis C virus (HCV) population is large with more than 2 million diagnosed, chronically infected cases throughout the G7 markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Many of these patients, including more than 270,000 with...

2014-06-28 13:57:32

TUM Virus infection supports organ acceptance Chronic hepatitis C virus infections are among the most common reasons for liver transplants. Because existing viruses also infect the new liver, the immune system is highly active there. Despite this, the new organ is not rejected, as scientists from the Helmholtz Zentrum München and the Technische Universität München (TUM) have now discovered. The long-term stimulation of the innate immune system by the virus actually increases the...

2014-06-18 12:29:54

Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON, Mass., June 18, 2014 /PRNewswire/ -- Decision Resources Group finds that China's market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated population, following the introduction of novel HCV therapies. Nearly a third of patients diagnosed with HCV do not receive the...

2014-06-17 04:21:28

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). Accelerated assessment, which is designated to new medicines of major public health...

2014-06-16 23:04:46

GIA announces the release of a comprehensive global report on Growth Factors (Blood and Tissue) markets. Global market for Growth Factors (Blood and Tissue) is forecast to reach US$48 billion by 2020, driven by growing demand for effective, cost-efficient therapeutics, and increasing significance of growth factors in the treatment of chemotherapy-associated anemia and neutropenia. San Jose, California (PRWEB) June 16, 2014 Follow us on LinkedIn – Fuelled by the growing importance of...

2014-06-13 16:23:26

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related